NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma ...
For oncologists navigating the rapidly evolving landscape of renal cell carcinoma (RCC), the data presented at the 2026 ASCO ...
This insight piece explores how treatment patterns in bladder cancer have shifted as immunotherapy options have expanded in community oncology. You’ll learn how combination regimens such as enfortumab ...
Price transparency compliance is often “in-form” rather than “in-spirit,” with many machine-readable files failing to provide complete, accurate, and usable drug pricing data. Reform priorities ...
Appropriate use of immune checkpoint inhibitors and immunotherapy differs in adults with unresectable, metastatic cutaneous ...
KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.
Clinicians must consider patient comorbidities and therapy safety when selecting immunotherapy for cSCC, says Todd ...
HealthDay News — For patients with asthma, receipt of immune checkpoint inhibitor (ICI) therapy for melanoma or renal cell carcinoma is not associated with an increased risk for exacerbations, ...
Pharmaceutical Technology on MSN
Targeted therapies to join chemo as oncology treatment backbone
Experts agree that combination approaches, which may or may not include chemotherapy, will drive improved patient outcomes in oncology.
FDA approved pembrolizumab plus paclitaxel ± bevacizumab for PD-L1 CPS ≥1 platinum-resistant ovarian/fallopian tube/primary peritoneal carcinoma after 1–2 prior systemic therapies. KEYNOTE-B96 ...
The median progression-free survival was 11.2 and 7.8 months with sacituzumab govitecan plus pembrolizumab and chemotherapy plus pembrolizumab, respectively. Sara M. Tolaney, MD, from the Dana-Farber ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results